Targeting IL-17 and TH17 cells in chronic inflammation
Don't expose yourself to heavy levels of toxicities
Potential for adverse effects: Uncontrolled ingredients and unpredictable dosages increase the risk of unpredictable and potentially severe side effects, beyond the known nausea, vomiting, and diarrhea
Health records and insurance claims data showed half (n = 85,015) started treatment with GLP-1 receptor agonists between 2013 and 2023
This is significantly less than brand-name Mounjaro or Zepbound, which exceed $1,000 per month without insurance
Your GLP-1 coverage, denied approved If Medicare denies Wegovy for CV risk reduction, Honest Care can help you build a strong appeal with evidence from the SELECT trial